Bladder Cancer
Conditions
Keywords
Detection of Bladder Cancer using NMP22 Urine Test Kit
Brief summary
It is hypothesized that the NMP22(Nuclear Matrix Protein) Bladder Check ® Test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cell carcinoma at high risk of recurrence.
Detailed description
Patients who have been previously treated for bladder cancer and are at a high risk for recurrence are being monitored for recurrence every 3 months with urine cytology and cystoscopy as part of standard care.The NMP22 Bladder Cancer ® Test Kit has been designed to provide an alternative to regular urine cytology. A urine sample will be provided and divided with a portion being used to assess the NMP22 test kit and the remaining sample to be sent to the lab for regular urine cytology. Patient charts will be reviewed by a medical student to record age, clinical stage, pathologic stage, time to disease progression/recurrence, site of recurrence and survival data.
Interventions
DEVICENuclear Matrix Protein 22 Urine sample kit
Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
Sponsors
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* · History of pTis, pT1, large (\>2cm) pTa or multiple pTa bladder cancer tumours. Written Informed Consent prior to any study-related procedures.
Exclusion criteria
* History of bladder cancer tumours other than those listed in inclusion
Countries
Canada
Outcome results
None listed